CNSP — CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals Q4 2019 Earnings Call Summary

1. Key Financial Results and Metrics:

• CNS Pharmaceuticals completed its IPO in November 2019, raising gross proceeds of $9.8 million.
• As of December 31, 2019, the company reported cash and cash equivalents of $7.2 million.
• General and Administrative (G&A) expenses for Q4 2019 were $1.0 million, up from $0.2 million in the prior year, reflecting increased operational costs post-IPO.
• Research and Development (R&D) expenses were $1.5 million for Q4 2019, compared to $0 in Q4 2018, primarily due to costs associated with Berubicin.
• The net change in cash for Q4 was $6.3 million, and the company anticipates needing to raise an additional $7 million to fund its Phase 2 trial, which is estimated to cost between $8 million and $13 million.

2. Strategic Updates and Business Highlights:

• CNS is focused on Berubicin, an anthracycline drug candidate for glioblastoma multiforme (GBM), which has shown promise in a prior Phase 1 trial with a 44% response rate.
• The company received positive feedback from the FDA regarding its IND application and plans to initiate a Phase 2 clinical study in the U.S. for Berubicin in approximately 60 patients in the second half of 2020.
• CNS has partnered with WPD Pharmaceuticals for additional clinical trials in Poland, which will mirror CNS's U.S. trials, potentially doubling the data available for FDA review.
• The company also announced WP1244, a new drug candidate aimed at treating brain cancers, which could allow for combination therapies with Berubicin.

3. Forward Guidance and Outlook:

• CNS expects to initiate clinical trials for Berubicin and WP1244 in 2020, with key milestones including the start of the Phase 2 study in the U.S. and the Phase 1 pediatric trial in Poland.
• The company aims to secure orphan drug designation from the FDA, which would provide market exclusivity for up to seven years post-NDA approval.
• The current cash position is projected to support operations into mid-2021, but additional funding will be necessary to complete the Phase 2 trial.

4. Bad News, Challenges, or Points of Concern:

• The company faces significant financial challenges, needing to raise additional capital to fund ongoing clinical trials.
• The high costs associated with clinical trials (estimated $8 million to $13 million for Phase 2) may pose a risk if funding is not secured.
• The competitive landscape for GBM treatments is intense, with limited effective options currently available, but the potential for new entrants could impact CNS's market position.

5. Notable Q&A Insights:

• The call did not include a detailed Q&A session, as the operator concluded the call shortly after management's remarks. However, management indicated their participation in upcoming investor conferences, suggesting ongoing engagement with the investment community.

Overall, CNS Pharmaceuticals is positioned to advance its clinical programs, but faces financial and operational challenges that will require careful management and additional funding to navigate successfully.